Guides
Research Guides
Short frameworks for reading biotech and pharmaceutical companies with more discipline.
Clinical Endpoints
Clinical endpoints define what a trial is trying to prove. For investors and industry readers, the key question is not only whether a p-value is positive, but whether the endpoint reflects meaningful patient benefit, regulatory relevance, and commercial differentiation.
Regulatory Milestones
IND clearance, Phase II data, pivotal trial design, NDA/BLA submission, advisory committees, and approval decisions each change the evidence package in different ways. Good analysis asks what uncertainty has been reduced, and what risk remains.
Biotech Valuation
Biotech valuation is a probability-weighted reading of clinical risk, market size, competitive positioning, financing needs, and strategic value. The goal is not precision for its own sake, but a disciplined map of assumptions.
BD and Licensing Terms
Upfront payments, milestones, royalties, option structures, territory rights, and development responsibilities reveal how partners allocate risk and value. The headline number is rarely the full story.
Safety and CMC Risk
A strong efficacy signal can still fail if safety, exposure, dosing, durability, or manufacturing cannot support clinical and commercial use. CMC is often where a scientific idea becomes an investable product or stalls.
Market Sizing
Good market sizing separates epidemiology, diagnosed patients, treatable patients, eligible patients, pricing, reimbursement, duration, and competitive share. The useful number is not the biggest number; it is the defensible number.
Patent and Competition
A drug's value depends not only on clinical data, but also on exclusivity, composition-of-matter protection, formulation and method patents, lifecycle strategy, and the competitive products arriving before or after it.
Cash Runway
Cash runway determines whether a company can reach its next value-changing milestone without dilutive financing. The important question is whether the cash balance matches the clinical plan and catalyst timeline.